| This week's sponsor is Navitas. | |  | |
Top Stories Thursday, July 21, 2016 Biogen’s long-standing CEO Dr. George Scangos is to step down from the company in “the coming months” as the Big Biotech looks for a successor. Thursday, July 21, 2016 It’s been a torrid first half for Aegerion Pharmaceuticals that began the year with a 25% cut to its staff, but the biotech is swinging the ax again--this time to a further 13% of its workers. Wednesday, July 20, 2016 Investors committed to digging deep to support the latest biotech IPO, yet again. But the strategy seems to be working. Gene therapy player Audentes Therapeutics priced at the midpoint of its range, raising $75 million, and then proceeded to move up about 10% in early trading on July 20. Thursday, July 21, 2016 Boston’s Rhythm has produced highly impressive results for its FDA “breakthrough” candidate setmelanotide in people with an ultra-rare genetic disease that causes early onset obesity due to insatiable hunger. Wednesday, July 20, 2016 Gene therapy player AveXis has grown into almost a $1 billion company since its IPO less than 6 months ago. Its latest bit of good news is a Breakthrough Therapy Designation for its only clinical candidate, AVXS-101 to treat spinal muscular atrophy Type 1. Thursday, July 21, 2016 Galderma Pharma has picked up the rights to a mid-phase atopic dermatitis and pruritus drug from Roche’s Chugai Pharmaceutical. The deal gives Galderma an exclusive license to develop and market the drug, the first biologic in its portfolio, in all countries except Japan and Taiwan. Monday, July 18, 2016 CRO giant Parexel has seen its chief financial officer and senior vice president Ingo Bank resign from the company over the weekend, according to a SEC filing. | | | As part of its plans announced back in April, AstraZeneca has begun closing its neuroscience unit in Cambridge, MA. Blog Cerecor has been given a $1 million R&D grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health. Release Californian biotech Xoma has received orphan drug designation in the European Union for XOMA 358 for the treatment of congenital hyperinsulinism. Statement San Diego’s Targazyme has enrolled its first patient in the Phase I/II study of TZ101 fucosylated regulatory T-cells to treat and prevent Graft vs. Host Disease in the transplant setting. Statement | |
|
Resources Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. This series provides an overview of the science and technology used to enable discovery and the processes scientists use to discover new therapeutics. Download now. Sponsored by: Speid & Associates, Inc. Do you have what it takes? Drug Development training does not have to be boring. The Drug Development Boot CampTM trains experienced researchers and drug developers in all major aspects of drug development, using an accelerated learning and total immersion approach. Click here to website. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. | 
